Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurofeedback Modulation of Immune Response to Hepatitis B Vaccine
NCT03951870Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jan 2019
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Randomised, single-blind trial (3 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Change in anti-HBs immunoglobulins in plasma at 6 weeks, Change in cytokines blood concentrations at 17 days and 1 more. Started Jan 2019; status: completed.
Beyond the preview
Go deeper on NCT03951870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951870.